Amgen’s Repatha Cuts Heart Attack Risk 25% in VESALIUS‑CV Trial, Boosting Investor Confidence
Amgen’s Repatha cuts first heart attack risk by 36% in VESALIUS‑CV, boosting investor confidence and market value.
2 minutes to read
Amgen Inc
Amgen Faces Governance Probe, Secures EU Approval for Tezspire, and Strengthens Market Position in Thrombocytopenia
Amgen Inc. experienced significant developments in the week of October 23, 2025, including a shareholder rights inquiry, regulatory approval for its respiratory therapy Tezspire, and recognition in the thrombocytopenia market, with its share price r…
2 minutes to read
Amgen Inc. Exceeds Expectations, Raises 2025 Outlook Amid Market Volatility
Amgen Inc. has exceeded expectations with a 9% revenue increase, prompting a revised 2025 revenue forecast and a $500 million share repurchase program.
2 minutes to read
Amgen Inc. Delivers Strong Q2 Results Amid Market Volatility, Highlights Growth and Innovation
Amgen Inc. reports a 9% increase in total revenues to $9.2 billion in Q2 2025, driven by its commitment to delivering innovative medicines and biosimilars.
3 minutes to read
Amgen’s MariTide Shows Promising Results in Phase 2 Obesity Study, Offers Hope for Type 2 Diabetes Patients
Amgen Inc. has announced promising results from its Phase 2 obesity study of MariTide, a potential groundbreaking treatment for obesity, particularly in patients with type 2 diabetes.
2 minutes to read